Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) have become the standard of care for several cancer types. The gene discussed is CTLA4; the disease is cancer.